Public research overviewHow we research Research team
Liquid Biopsy: Executive Summary and Strategic Context
Liquid biopsy analyzes disease-associated material, including circulating tumor DNA, circulating tumor cells, cell-free DNA, and extracellular vesicles, from blood or other bodily fluids. Its clinical value is linked to minimally invasive sampling, repeat testing, and the potential to characterize disease biology when tissue is limited or difficult to obtain. Applications span cancer detection research, molecular profiling, treatment selection, residual disease assessment, and monitoring of treatment response or resistance. Analytical validity, clinical utility, standardized workflows, and reimbursement remain central determinants of adoption.
360iResearch introduction
Inside the research
Coverage at a glance
Selected branches from the published table of contents. Follow a chapter to see every subchapter in context.
Chapter 7 Offering
- Testing Services
- Products
Chapter 8 Specimen
- Blood-Derived Specimens
- Urine
- Serous Cavity Fluids
- Cerebrospinal Fluid
Chapter 9 Target Analyte
- Cell-Free Nucleic Acids
- Circulating Tumor Cells
- Protein & Peptide Signatures
- Multi-Analyte Signatures
How Liquid Biopsy Is Reshaping Precision Diagnostics
The field is shifting from proof-of-concept testing toward clinically integrated workflows. Greater attention is being placed on pre-analytical handling, assay sensitivity, quality control, and reporting standards because low-abundance biomarkers can be affected by collection, transport, extraction, and sequencing choices. Multi-analyte approaches are also gaining importance as researchers seek to combine genomic, epigenomic, transcriptomic, and protein signals. The resulting landscape favors evidence-based deployment in settings where serial, minimally invasive assessment can complement-rather than automatically replace-tissue-based diagnosis.
Artificial Intelligence Strengthens Signal Detection and Clinical Interpretation
Artificial intelligence can support liquid biopsy by identifying complex molecular patterns, improving variant classification, integrating longitudinal measurements, and helping distinguish disease-associated signals from background biological variation. Machine-learning methods may also assist quality assessment and interpretation of fragmented or low-frequency signals. However, dependable use requires representative training data, external validation, transparent performance assessment, and safeguards against bias and overinterpretation. Human clinical review, laboratory governance, and adherence to applicable diagnostic and data-protection requirements remain essential.
Regional Insights: Regulation, Infrastructure, and Clinical Integration
North America is characterized by advanced molecular-diagnostics infrastructure, active translational research, and comparatively mature pathways for clinical validation, while reimbursement and evidence requirements continue to shape routine use. Europe combines strong academic and hospital networks with a more harmonized policy direction through the European Union, although national reimbursement and implementation practices vary. Asia-Pacific includes highly capable research and manufacturing ecosystems alongside substantial differences in laboratory access, regulatory maturity, and healthcare financing. Latin America is developing capacity through specialist laboratories and international collaboration, but access, logistics, and reimbursement can constrain adoption. The Middle East is investing in precision-health infrastructure and specialized care, with implementation influenced by national strategies and referral patterns. Africa presents significant potential for minimally invasive approaches, while laboratory networks, sample transport, affordability, and workforce capacity remain important practical considerations.
Group Insights Across ASEAN, BRICS, EU, G7, GCC, and NATO
ASEAN’s diverse health systems create opportunities for regional laboratory partnerships, but cross-border standards, reimbursement, and access differ materially among members. BRICS countries bring substantial scientific, manufacturing, and clinical capabilities, while regulatory alignment and uneven infrastructure remain relevant to coordinated deployment. The European Union benefits from shared policy initiatives and cross-border research frameworks, yet national health-technology assessment and procurement decisions still matter. G7 members generally have strong clinical research, regulatory, and diagnostic ecosystems, with evidence generation and affordability shaping wider implementation. GCC countries are expanding specialized healthcare and genomic capabilities, often through centralized programs and international partnerships. NATO is not a healthcare market bloc, but its members collectively include advanced biomedical systems and may benefit from interoperability, resilience planning, and secure data practices in diagnostic networks.
Country Insights: Diverse Pathways to Clinical Adoption
The United States and Canada combine strong research ecosystems with sophisticated laboratory and specialty-care networks, while coverage, evidence, and regulatory considerations influence access. Germany, France, Italy, Spain, and the United Kingdom have established oncology infrastructure and active translational research, but national and regional approaches to assessment, procurement, and reimbursement differ. China, Japan, South Korea, India, and Australia are strengthening precision-medicine capabilities through research institutions, hospital networks, and technology development; implementation varies with regulatory pathways, data governance, and healthcare access. Brazil, Mexico, and Russia have important specialist centers and scientific capacity, while regional disparities, laboratory availability, and financing can affect routine use. Across all listed countries, clinical utility, test quality, turnaround time, and integration with multidisciplinary care are more consequential than analytical capability alone.
Priorities for Leaders Building Reliable Liquid Biopsy Programs
Industry leaders should define a narrow clinical use case first and generate prospective evidence tied to a clear management decision or patient outcome. They should standardize collection, stabilization, processing, and quality-control procedures across sites, then validate performance in populations that reflect intended clinical use. Partnerships with hospitals, reference laboratories, regulators, and health-technology assessment bodies can clarify evidentiary and reimbursement expectations early. Organizations should also establish transparent AI governance, including dataset documentation, independent validation, drift monitoring, cybersecurity, and clinician oversight. Finally, scalable implementation should prioritize interoperable reporting, workforce training, equitable access, and continuous post-deployment surveillance.
Research Methodology: Evidence-Centered Assessment of Liquid Biopsy
This executive summary uses a structured synthesis of the liquid-biopsy field, emphasizing peer-reviewed clinical and translational research, regulatory and professional guidance, publicly available health-system information, and documented laboratory-practice principles. Findings are organized around technology evolution, clinical utility, artificial intelligence, geography, and implementation requirements. Regional, group, and country observations are presented qualitatively to avoid unsupported numerical claims. Interpretation distinguishes analytical performance from clinical validity and clinical utility, and recognizes that regulatory status, reimbursement, laboratory infrastructure, and standards can differ by indication and jurisdiction. No market estimates, market shares, forecasts, or company-specific claims are used.
Conclusion: Evidence and Implementation Will Define Liquid Biopsy’s Next Phase
Liquid biopsy offers a practical route to more frequent and less invasive molecular assessment, particularly when tissue sampling is limited or serial monitoring is clinically valuable. Its long-term contribution will depend on demonstrating that test results improve decisions and outcomes, not simply that biomarkers can be detected. Progress therefore requires rigorous validation, standardized workflows, responsible AI, clear reporting, and equitable integration into care pathways. Leaders that align scientific performance with clinical utility, regulatory expectations, and real-world implementation will be best positioned to translate liquid-biopsy capabilities into dependable patient benefit.
Research report
Table of contents
- 1.Preface
- 1.1Objectives of the Study
- 1.2Market Definition
- 1.3Market Segmentation & Coverage
- 1.4Years Considered for the Study
- 1.5Currency Considered for the Study
- 1.6Language Considered for the Study
- 1.7Key Stakeholders
- 2.Research Methodology
- 2.1Introduction
- 2.2Research Design
- 2.2.1Primary Research
- 2.2.2Secondary Research
- 2.3Research Framework
- 2.3.1Qualitative Analysis
- 2.3.2Quantitative Analysis
- 2.4Market Size Estimation
- 2.4.1Top-Down Approach
- 2.4.2Bottom-Up Approach
- 2.5Data Triangulation
- 2.6Research Outcomes
- 2.7Research Assumptions
- 2.8Research Limitations
- 3.Executive Summary
- 3.1Introduction
- 3.2CXO Perspective
- 3.3New Revenue Opportunities
- 3.4Next-Generation Business Models
- 3.5Industry Roadmap
- 4.Market Overview
- 4.1Introduction
- 4.2Industry Ecosystem & Value Chain Analysis
- 4.2.1Supply-Side Analysis
- 4.2.2Demand-Side Analysis
- 4.2.3Stakeholder Analysis
- 4.3Market Dynamics
- 4.3.1Key Drivers
- 4.3.1.1Precision-oncology treatment selection and evolving resistance
- 4.3.1.2Serial residual-disease and recurrence surveillance
- 4.3.1.3Investment in blood-based early detection and screening
- 4.3.1.4Rising cancer burden and unmet diagnostic need
- 4.3.2Key Restraints
- 4.3.2.1Unresolved clinical utility and follow-up economics in broad screening
- 4.3.2.2Selective reimbursement and indication-specific evidence requirements
- 4.3.2.3Biological signal limitations and continued tissue complementarity
- 4.3.2.4Fragmented regulatory pathways and compliance burden
- 4.3.3Key Opportunities
- 4.3.3.1Longitudinal molecular residual disease and recurrence programs
- 4.3.3.2Risk-stratified screening linked to complete diagnostic pathways
- 4.3.3.3Localized hybrid laboratory networks in expanding and underserved regions
- 4.3.3.4Integrated interpretation and multi-analyte workflow software
- 4.3.4Key Challenges
- 4.3.4.1Pre-analytical consistency across distributed specimen networks
- 4.3.4.2Converting analytical performance into decision-changing clinical utility
- 4.3.4.3Affordability, infrastructure, and equitable access constraints
- 4.3.4.4Managing hybrid delivery, data, and portfolio complexity
- 4.3.1Key Drivers
- 4.4Porter’s Five Forces Analysis
- 4.5PESTLE Analysis
- 4.6Market Outlook
- 4.6.1Near-Term Market Outlook (0–2 Years)
- 4.6.2Medium-Term Market Outlook (3–5 Years)
- 4.6.3Long-Term Market Outlook (5–10 Years)
- 4.7Go-to-Market Strategy
- 5.Market Insights
- 5.1Consumer Insights & End-User Perspective
- 5.2Consumer Experience Benchmarking
- 5.3Opportunity Mapping
- 5.4Distribution Channel Analysis
- 5.5Pricing Trend Analysis
- 5.6Regulatory Compliance & Standards Framework
- 5.7ESG & Sustainability Analysis
- 5.8Disruption & Risk Scenarios
- 5.9Return on Investment & Cost-Benefit Analysis
- 6.Cumulative Impact of Artificial Intelligence 2026
- 7.Liquid Biopsy Market, by Offering
- 7.1Introduction
- 7.2Testing Services
- 7.2.1Clinical Testing Services
- 7.2.2Biopharma & Research Testing Services
- 7.3Products
- 7.3.1Assay Kits & Reagents
- 7.3.2Instruments & Integrated Systems
- 7.3.3Analyte Isolation & Enrichment Products
- 7.3.4Specimen Collection & Preservation Products
- 7.3.5Bioinformatics & Interpretation Software
- 8.Liquid Biopsy Market, by Specimen
- 8.1Introduction
- 8.2Blood-Derived Specimens
- 8.2.1Plasma
- 8.2.2Whole Blood
- 8.2.3Serum
- 8.3Urine
- 8.4Serous Cavity Fluids
- 8.4.1Pleural Effusion
- 8.4.2Ascites & Peritoneal Fluid
- 8.5Cerebrospinal Fluid
- 8.6Saliva & Oral Rinses
- 8.7Ocular Fluids
- 9.Liquid Biopsy Market, by Target Analyte
- 9.1Introduction
- 9.2Cell-Free Nucleic Acids
- 9.2.1Cell-Free DNA
- 9.2.1.1Genomic Variant Signals
- 9.2.1.2DNA Methylation Signals
- 9.2.1.3Fragmentomic Signals
- 9.2.2Cell-Free RNA
- 9.2.2.1MicroRNA & Other Non-Coding RNA
- 9.2.2.2Messenger RNA
- 9.2.1Cell-Free DNA
- 9.3Circulating Tumor Cells
- 9.4Protein & Peptide Signatures
- 9.5Multi-Analyte Signatures
- 9.6Extracellular Vesicles
- 9.7Circulating Chromatin & Nucleosomes
- 9.8Metabolite & Glycan Signatures
- 10.Liquid Biopsy Market, by Analytical Platform
- 10.1Introduction
- 10.2Next-Generation Sequencing
- 10.2.1Targeted Sequencing
- 10.2.2Genome-Scale Sequencing
- 10.3Polymerase Chain Reaction
- 10.3.1Digital PCR
- 10.3.2Real-Time PCR
- 10.4Immunoassay
- 10.5Rare-Cell Analysis
- 10.5.1Affinity-Based Cell Enrichment
- 10.5.2Physical-Property Cell Enrichment
- 10.5.3Enrichment-Free Cell Imaging
- 10.6Mass Spectrometry
- 11.Liquid Biopsy Market, by Application
- 11.1Introduction
- 11.2Molecular Profiling & Therapy Selection
- 11.3Molecular Residual Disease & Recurrence Surveillance
- 11.4Drug Development & Clinical Research
- 11.5Screening & Early Detection
- 11.5.1Multi-Cancer Early Detection
- 11.5.2Single-Cancer Screening
- 11.6Treatment Response & Resistance Monitoring
- 11.7Prognosis & Risk Stratification
- 11.8Diagnostic Resolution & Tumor Localization
- 12.Liquid Biopsy Market, by Cancer Indication
- 12.1Introduction
- 12.2Solid Tumor Coverage
- 12.2.1Broad Solid-Tumor Coverage
- 12.2.2Digestive System Cancers
- 12.2.3Genitourinary Cancers
- 12.2.4Breast Cancer
- 12.2.5Thoracic Cancers
- 12.2.6Gynecologic Cancers
- 12.2.7Skin Cancers
- 12.2.8Head & Neck Cancers
- 12.2.9Brain & Central Nervous System Cancers
- 12.2.10Endocrine Cancers
- 12.2.11Cancers of Unknown Primary
- 12.2.12Bone & Soft-Tissue Sarcomas
- 12.2.13Ocular Cancers
- 12.3Multi-Cancer Coverage
- 12.4Hematologic Malignancies
- 13.Liquid Biopsy Market, by End User
- 13.1Introduction
- 13.2Healthcare Providers
- 13.2.1Hospitals & Cancer Centers
- 13.2.2Physician Practices & Specialty Clinics
- 13.3Clinical Laboratories
- 13.3.1Independent & Specialty Laboratories
- 13.3.2Hospital & Health-System Laboratories
- 13.4Life Sciences Companies & Contract Research Organizations
- 13.5Academic & Translational Research Institutions
- 13.6Health Plans & Employer Programs
- 13.7Government & Population-Screening Programs
- 14.Liquid Biopsy Market, by Delivery Model
- 14.1Introduction
- 14.2Centralized Provider-Operated Testing
- 14.3Decentralized Customer-Laboratory Testing
- 14.3.1Fully On-Premises Deployment
- 14.3.2Cloud-Assisted Deployment
- 15.Liquid Biopsy Market, by Region
- 15.1Introduction
- 15.2North America
- 15.3Europe
- 15.4Asia-Pacific
- 15.5Latin America
- 15.6Middle East
- 15.7Africa
- 16.Liquid Biopsy Market, by Group
- 16.1Introduction
- 16.2NATO
- 16.3G7
- 16.4European Union
- 16.5BRICS
- 16.6ASEAN
- 16.7GCC
- 17.Liquid Biopsy Market, by Country
- 17.1Introduction
- 17.2United States
- 17.3China
- 17.4Japan
- 17.5Germany
- 17.6United Kingdom
- 17.7France
- 17.8Italy
- 17.9Canada
- 17.10Brazil
- 17.11South Korea
- 17.12Spain
- 17.13Australia
- 17.14India
- 17.15Russia
- 17.16Mexico
- 18.Competitive Landscape
- 18.1Market Share Analysis, 2025
- 18.2Market Concentration Analysis, 2025
- 18.2.1Concentration Ratio (CR)
- 18.2.2Herfindahl Hirschman Index (HHI)
- 18.3Recent Developments & Impact Analysis, 2025
- 18.4Product Portfolio Analysis, 2025
- 18.5Benchmarking Analysis, 2025
- 19.Company Profiles
- 19.1Guardant Health, Inc.
- 19.2Foundation Medicine, Inc.
- 19.3Natera, Inc.
- 19.4GRAIL, Inc.
- 19.5Abbott Laboratories
- 19.6Tempus AI, Inc.
- 19.7Illumina, Inc.
- 19.8Thermo Fisher Scientific Inc.
- 19.9QIAGEN N.V.
- 19.10Menarini Silicon Biosystems
- 19.11Sysmex Corporation
- 19.12Caris Life Sciences, Inc.
- 19.13Labcorp Holdings Inc.
- 19.14Quest Diagnostics Incorporated
- 19.15Burning Rock Biotech Limited
- 19.16ANGLE plc
- 19.17Lucence
- 19.18Mirxes Holding Company Limited
- 19.19Geneseeq Technology Inc.
- 19.20MedGenome
- 19.21Freenome, Inc.
- 19.22Personalis, Inc.
- 19.23NeoGenomics Laboratories, Inc.
- 19.24BillionToOne, Inc.
- 19.25DELFI Diagnostics, Inc.
- 19.26Gene Solutions Genomics Pte. Ltd.
- 20.Key Experts